Seres Therapeutics, Inc.
MCRB
$9.31
-$0.77-7.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 64.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 64.00K |
| Cost of Revenue | 5.13M | 2.96M | 17.88M | 21.70M | 3.02M |
| Gross Profit | -5.13M | -2.96M | -17.88M | -21.70M | -3.02M |
| SG&A Expenses | 12.46M | 12.71M | 16.06M | 15.47M | 13.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -2.59M | 2.42M | -- |
| Total Operating Expenses | 28.84M | 29.17M | 31.35M | 39.59M | 37.02M |
| Operating Income | -28.84M | -29.17M | -31.35M | -39.59M | -37.02M |
| Income Before Tax | -15.64M | -51.04M | -32.87M | -40.13M | -34.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.64M | -51.04M | -32.87M | -40.13M | -34.72M |
| Earnings from Discontinued Operations | 0.00 | 139.81M | -- | -- | -6.53M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.64M | 88.78M | -32.87M | -40.13M | -41.25M |
| EBIT | -28.84M | -29.17M | -31.35M | -39.59M | -37.02M |
| EBITDA | -27.75M | -27.77M | -29.93M | -38.03M | -35.39M |
| EPS Basic | -1.83 | 11.63 | -4.34 | -5.49 | -6.34 |
| Normalized Basic EPS | 0.15 | -4.18 | -2.71 | -3.43 | -3.34 |
| EPS Diluted | -1.89 | 11.63 | -4.40 | -5.49 | -6.36 |
| Normalized Diluted EPS | 0.15 | -4.18 | -2.71 | -3.43 | -3.34 |
| Average Basic Shares Outstanding | 8.57M | 7.63M | 7.58M | 7.31M | 6.51M |
| Average Diluted Shares Outstanding | 8.57M | 7.63M | 7.58M | 7.31M | 6.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |